Kailera Secures $600M to Advance Dual-Targeting Obesity Drug to Global Phase 3 Tests

Bain Capital Private Equity led Kailera Therapeutics’ Series B financing, which will support global Phase 3 tests of KAI-9531, a weekly injectable drug that hits the same targets as Eli Lilly’s blockbuster obesity medication, Zepbound. The capital will also support development of other oral and injectable metabolic medicines in Kailera’s pipeline. The post Kailera Secures…

Read More

California’s Health Insurance Marketplace Braces for Chaos as Shutdown Persists

California this week plans to notify Affordable Care Act marketplace enrollees that their costs could rise sharply next year unless Congress extends subsidies to help people buy health insurance. Health care analysts say the nation’s uninsured population will rise significantly if federal lawmakers do not agree to renew covid-era tax credits, which Congress authorized in…

Read More